23 research outputs found
Auricular Acupuncture at the “Shenmen” and “Point Zero” Points Induced Parasympathetic Activation
Purpose. Since auricular acupuncture is a diagnostic and treatment system based on normalizing the body’s dysfunction, auricular acupuncture has been applied for pain relief, relaxation, and so on. These techniques would modulate the autonomic nerve system, thereby inducing the above-mentioned effects. The aim was to see the effect of auricular acupuncture applied to the “Shenmen” and “Point Zero” points on the postoperative heart rate variability (HRV). Methods. Twenty-six patients who underwent hemicolectomy under general anesthesia were randomized into the control or the acupuncture group. After the operation and before emergence, the acupuncture group received auricular acupuncture. An electrocardiographic unit was placed for recording the autonomic nervous activities. Results. The low frequency (LF)/high frequency (HF) ratio of HRV increased () in the control, but the ratio in the acupuncture did not change. There were significant differences between the ratios of the two groups at 3 : 00, 4 : 00, and 5 : 00. HF of the acupuncture group tended to be higher. HFs of the acupuncture group were significantly higher than those of the control group at 3 : 00, 4 : 00, and 5 : 00. Conclusion. Auricular acupuncture kept the LF/HF ratio at lower levels and HF at higher levels during postoperative period in the patients who had undergone hemicolectomy
Transcutaneous Electrical Nerve Stimulation on the PC-5 and PC-6 Points Alleviated Hypotension after Epidural Anaesthesia, Depending on the Stimulus Frequency
Neuraxial blockade causes arterial hypotension. Transcutaneous electrical nerve stimulation (TENS) at the Neiguan (PC-6) and Jianshi (PC-5) reduces the severity of hypotension after spinal anaesthesia, but did not clarify the optimal stimulus frequency. We hypothesized that the stimulus frequency of TENS at the PC-6 and PC-5 points would influence the severity of hypotension after epidural anaesthesia. 65 ASA I or II male patients presenting for inguinal hernia repair were randomized to five groups: the control group received no treatment; the 2 Hz, 10 Hz, 20 Hz, and 40 Hz groups received TENS at a frequency of 2 Hz, 10 Hz, 20 Hz, and 40 Hz, respectively. The lowest SBP was significantly higher in the 40 Hz group [the control, 84 (74–110) mmHg; the 2 Hz, 96 (62–116) mmHg; the 10 Hz, 100 (68–110) mmHg; the 20 Hz, 96 (64–115) mmHg; the 40 Hz, 104 (75–140) mmHg: P = 0.004]. Significantly less patients experienced hypotension in the 40 Hz group [the control, 78%; the 2 Hz, 43%; the 10 Hz, 38%; the 20 Hz, 38%; the 40 Hz, 8%: P = 0.008]. TENS on the PC-6 and PC-5 points reduced the severity and incidence of hypotension after epidural anaesthesia, depending on the stimulus frequency
The Effect of the Kampo
Background. Preoperative anxiety can lead to unfavorable physiological response such as tachycardia and hypertension. Prevention of preoperative anxiety improves surgical outcome and decreases inpatient stay. Yokukansan is one of prescriptions in Kampo, traditional Japanese herbal medicine, and is known to exert anxiolytic effects. The aim of the present study was to compare the effects of diazepam and Yokukansan on preoperative anxiety, salivary amylase activity, and sedation levels. Methods. Seventy American Society of Anesthesiologists physical status I or II patients presenting for hemicolectomy under general anesthesia combined with epidural anesthesia were enrolled. The Diazepam group received diazepam 5 mg orally and the Yokukansan group received Yokukansan 2.5 g orally. Results. Although levels of anxiety and salivary amylase activity were not different between the two groups, the modified Observer’s Assessment of Alertness/Sedation Scale of the Yokukansan group was significantly higher compared to that of the Diazepam group. Conclusion. Yokukansan alleviated preoperative anxiety without undesirable sedation, when compared with diazepam
How many times can patients tolerate reoperation?
The frequency of resection for the recurrence of colorectal cancer has not been investigated in previous studies. Likewise, the related postoperative complications and the limit for indicating surgical resection has not been reported. Herein, we reported the complications of a highly frequent surgical approach for rectal cancer recurrence, i.e., exceeding three reoperations, based on our clinical experience. We included 15 cases exceeding two operations for the local recurrence of colorectal cancer from 2014 to 2019. We examined the postoperative complications classified as Clavien–Dindo IIIb. The positive rates of the complications were 0 (0.0%), 0 (0.0%), 2 (13.3%), 3 (37.5%), and 0 (0.0%) for the primary, 1st recurrent, 2nd recurrent, 3rd recurrent, and 4th recurrent operation group (p = 0.027), respectively. It is important to exercise caution in handling cases exceeding two reoperations (exceeding three reoperations including the primary operation)
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
A novel series of
non-amidine-based C1s inhibitors have
been explored.
Starting from high-throughput screening hit 3, isoquinoline
was replaced with 1-aminophthalazine to enhance C1s inhibitory activity
while exhibiting good selectivity against other serine proteases.
We first disclose a crystal structure of a complex of C1s and a small-molecule
inhibitor (4e), which guided structure-based optimization
around the S2 and S3 sites to further enhance C1s inhibitory activity
by over 300-fold. Improvement of membrane permeability by incorporation
of fluorine at the 8-position of 1-aminophthalazine led to identification
of (R)-8 as a potent, selective, orally
available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation
induced by human serum in a dose-dependent manner in an in vitro assay
system, proving that selective C1s inhibition blocked the classical
complement pathway effectively. As a result, (R)-8 emerged as a valuable tool compound for both in vitro
and in vivo assessment
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
A novel series of
non-amidine-based C1s inhibitors have
been explored.
Starting from high-throughput screening hit 3, isoquinoline
was replaced with 1-aminophthalazine to enhance C1s inhibitory activity
while exhibiting good selectivity against other serine proteases.
We first disclose a crystal structure of a complex of C1s and a small-molecule
inhibitor (4e), which guided structure-based optimization
around the S2 and S3 sites to further enhance C1s inhibitory activity
by over 300-fold. Improvement of membrane permeability by incorporation
of fluorine at the 8-position of 1-aminophthalazine led to identification
of (R)-8 as a potent, selective, orally
available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation
induced by human serum in a dose-dependent manner in an in vitro assay
system, proving that selective C1s inhibition blocked the classical
complement pathway effectively. As a result, (R)-8 emerged as a valuable tool compound for both in vitro
and in vivo assessment
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
A novel series of
non-amidine-based C1s inhibitors have
been explored.
Starting from high-throughput screening hit 3, isoquinoline
was replaced with 1-aminophthalazine to enhance C1s inhibitory activity
while exhibiting good selectivity against other serine proteases.
We first disclose a crystal structure of a complex of C1s and a small-molecule
inhibitor (4e), which guided structure-based optimization
around the S2 and S3 sites to further enhance C1s inhibitory activity
by over 300-fold. Improvement of membrane permeability by incorporation
of fluorine at the 8-position of 1-aminophthalazine led to identification
of (R)-8 as a potent, selective, orally
available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation
induced by human serum in a dose-dependent manner in an in vitro assay
system, proving that selective C1s inhibition blocked the classical
complement pathway effectively. As a result, (R)-8 emerged as a valuable tool compound for both in vitro
and in vivo assessment
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
A novel series of
non-amidine-based C1s inhibitors have
been explored.
Starting from high-throughput screening hit 3, isoquinoline
was replaced with 1-aminophthalazine to enhance C1s inhibitory activity
while exhibiting good selectivity against other serine proteases.
We first disclose a crystal structure of a complex of C1s and a small-molecule
inhibitor (4e), which guided structure-based optimization
around the S2 and S3 sites to further enhance C1s inhibitory activity
by over 300-fold. Improvement of membrane permeability by incorporation
of fluorine at the 8-position of 1-aminophthalazine led to identification
of (R)-8 as a potent, selective, orally
available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation
induced by human serum in a dose-dependent manner in an in vitro assay
system, proving that selective C1s inhibition blocked the classical
complement pathway effectively. As a result, (R)-8 emerged as a valuable tool compound for both in vitro
and in vivo assessment
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway
A novel series of
non-amidine-based C1s inhibitors have
been explored.
Starting from high-throughput screening hit 3, isoquinoline
was replaced with 1-aminophthalazine to enhance C1s inhibitory activity
while exhibiting good selectivity against other serine proteases.
We first disclose a crystal structure of a complex of C1s and a small-molecule
inhibitor (4e), which guided structure-based optimization
around the S2 and S3 sites to further enhance C1s inhibitory activity
by over 300-fold. Improvement of membrane permeability by incorporation
of fluorine at the 8-position of 1-aminophthalazine led to identification
of (R)-8 as a potent, selective, orally
available, and brain-penetrable C1s inhibitor. (R)-8 significantly inhibited membrane attack complex formation
induced by human serum in a dose-dependent manner in an in vitro assay
system, proving that selective C1s inhibition blocked the classical
complement pathway effectively. As a result, (R)-8 emerged as a valuable tool compound for both in vitro
and in vivo assessment